Eli Lilly Technical Analysis - Eli Lilly Trading: 2022-02-03

Eli Lilly is an American pharmaceutical company which develops and sells human pharmaceuticals worldwide. Its global competitors include companies like GlasxoSmithKline, Bristol-Myers Squibb, Merck, Pfizer and others. Eli Lilly capitalization is about $227.5 billion and the stock is trading at P/E ratio (Trailing Twelve Months) of 63.3 currently and Forward P/E of around 27.6 compared with the 24.3 Forward P/E of the pharmaceutical industry as a whole. The company earned $27.76B revenue (ttm) and Return on Equity (ttm) of 92.24%. Since the beginning of 2017, Eli Lilly has outperformed all other big pharmaceutical companies: from January 1, 2017 through December 10, 2021 Eli Lilly stock generated a 270% total return, more than any of its competitors during the same time frame. Last Friday Eli Lilly announced plans to invest over $1 billion to create a new manufacturing site in Concord, North Carolina. Over the last five years, the company has invested over $4 billion in global manufacturing, including more than $2 billion in the US. The company also announced plans to invest $500 million in a new biopharmaceutical manufacturing facility in Limerick, Ireland. Drugs that analysts expect will account for majority of company’s revenue increase in 2022 include Jardiance, a type 2 diabetes treatment it markets in partnership with Boehringer Ingelheim, and Tyvyt, a PD-1 inhibitor Lilly jointly developed in China with collaboration partner Innovent Biologics. Eli Lilly's stock price is retracing up to its all-time high after falling over 10% since the start of 2022. While the company has missed earnings expectations in three of the trailing four quarters and beat in one, the consensus forecast is Lilly should beat expectations when it reports fourth-quarter and full-year results today.